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Some of the most famous and beloved 
artworks were created by artists who suf-
fered from serious mental disorders, such as 
schizophrenia. One of my favorite paintings 
is The Solitary Cedar by the Hungarian art-
ist Tivadar Kosztka Csontváry (Figure 1). 
Csontváry lived at the turn of the 19th cen-
tury under the Austro-Hungarian Empire, 
and worked as a licensed pharmacist until 
he heard voices insisting that he give up his 
civil profession and devote his life to paint-
ing. He traveled around Europe, studied 
painting and developed a very individual 
style. Some of his most amazing works were 
created in a relatively short period of time. 
I have been wondering since my student 
years, how much his illness, his schizophre-
nia contributed to his work. This question 
could be debated either from an aesthetic 
or a scientiﬁ  c point of view. Was his schizo-
phrenia fundamental to his creativity; did 
his illness deﬁ  ne his individual artistic style? 
If yes, then one can argue that treatment 
of his condition could have fundamentally 
changed the way he painted. On the other 
hand, schizophrenia also prevented him 
reaching his full potential as an artist. We 
know that his creative period was short-
lived as his illness progressed rapidly and 
he was not able to complete his paintings. 
Eventually he could not paint at all.
Would Csontváry have been luckier liv-
ing in our recent time? Would currently 
available therapies have helped him ﬁ  nish 
his paintings? Difﬁ  cult to answer. No one 
questions the progress psychiatry has made 
over the last century. Diagnostic accuracy 
has improved with clinically better deﬁ  ned 
sub-types of the disease. The discovery, 
more than 50 years ago, that the antihis-
tamine agent, chlorpromazine calmed 
agitated psychiatric patients opened a new 
era in psychiatry and antipsychotic drug 
research. It was soon recognized that chlo-
rpromazine and other related compounds 
(referred to as neuroleptics) induced not 
only sedation but also a diminution of 
positive symptoms of schizophrenia, such 
as hallucinations and delusions. The sub-
sequent recognition of a strong  correlation 
between clinical potency of neuroleptic 
agents and their ability to block dopamine 
D2-type receptors suggests that dopamin-
ergic hyperactivity might represent a 
critical pathophysiological event in schiz-
ophrenia. Consistent with this, dopamin-
ergic hyperactivity has been conﬁ  rmed in 
schizophrenia patients using in vivo imag-
ing studies, and all current agents for treat-
ing schizophrenia function primarily by 
blocking dopamine D2 receptors.
However, dopaminergic hyperactivity 
is seen only in a subset of patients during 
the acute stages of the illness, and it is now 
generally understood that dopamine is not 
the only (or even the main) dysfunctional 
neurotransmitter system in this disease. In 
fact, in addition to dopamine, practically 
all known classical neurotransmitters, or at 
least their receptors have been linked to the 
disease, including glutamate, GABA, sero-
tonin, norepinephrine, acetylcholine and a 
variety of neuropeptides and endogenous 
neuromodulators, such as the endorphins 
and endocannabinoids. Genetic studies 
have so far contributed little for clarify-
ing and understanding the critical neuro-
transmission abnormalities in the disease, 
although several affected genes (includ-
ing neuregulin, dysbindin, DISC1, DAAO, 
GRM3, and G72) may indicate a dysfunc-
tional NMDA receptor-mediated glutamate 
transmission. Considering the plasticity and 
dynamic feature of the brain, one can argue 
that alteration in any of the main brain neu-
rotransmitter systems would subsequently 
inﬂ  uence other neurotransmitters as well. 
Therefore, probably the best approach to 
understand brain dysfunctions associated 
with schizophrenia would be based on neu-
ronal circuits, where interactions between 
various neurotransmitter systems identiﬁ  ed 
within speciﬁ  c neuronal pathways and net-
works could be integrated.
It is recognized that schizophrenia is a 
genetically predisposed disease, and like 
other complex disorders it is character-
ized by the contribution of multiple risk 
genes in combination with epigenetic and 
environmental processes leading to the 
development of the disease. However, it is 
still a major challenge for the forthcom-
ing years to determine whether a relatively 
few highly penetrant but rare major genetic 
deﬁ  cits would determine the disease, or a 
large number of genes would contribute 
although each gene accounting for only 
a small increment in risk. Interestingly, 
a recent genome-wide search of copy 
number variants (CNVs) revealed associa-
tion between CNVs of certain high pen-
etrant genes not only with schizophrenia, 
but also other psychiatric illnesses, such as 
autism and bipolar disorder. These ﬁ  ndings 
might point to the fact that most psychiat-
ric diseases share a number of symptoms 
therefore these genetic abnormalities might 
correlate better with symptoms of various 
psychiatric disorders rather than with a sin-
gular psychiatric disease itself. The concept 
and application of endophenotypes better 
deﬁ  ne this relationship: endophenotypes 
capture and measure pathophysiological 
signals contributing to the clinical mani-
festation of the disease. Neurophysiological 
abnormalities associated with schizophre-
nia could be considered as endophenotypes; 
their value in genetic studies of schizophre-
nia has already been demonstrated. Future 
research to model neurophysiological 
abnormalities of schizophrenia (patho-
physiological endophenotypes) in animal 
experiments will be required to use these 
endophenotypes as translational biomark-
ers to bridge experimental studies to clini-
cal development.
During the last two or three decades, 
huge investments have been made in schizo-
phrenia research by academic institutes as 
well as the drug industry, with only modest 
progress. In clinical practice a wide array 
of safe antipsychotics exist with differen-
tiated side-effect proﬁ  les. However, many 
critical symptoms of the disease are still 
not impacted by the current treatments. 
Most signiﬁ  cantly, it has been recognized 
that patients’ cognitive function is the main 
factor determining their everyday func-
tioning in the society. No drugs currently 
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designing the best pharmacotherapy for 
patients based on their individual genetic 
characteristics.
Hypothesis-driven research is the cor-
nerstone of scientiﬁ  c discovery, but some-
times a hypothesis can become a dogma, 
slowing down the progress of discovery. 
Sometimes our experimental ﬁ  ndings do 
not mold easily into our pre-fabricated con-
cepts and hypothesis. I hope that Frontiers 
in Schizophrenia will support all the efforts 
which question current status quo and it 
will provide a forum for new ideas and 
open debate. We need new approaches 
and new concepts. We need them for our 
patients so that they can pursue whatever 
they want to do in their life, if not for any 
other reason than just to paint lonely cedars 
in Lebanon.
Received: 02 March 2010; accepted: 02 March 2010; 
  published online: 17 March 2010.
Citation: Hajós M (2010) Challenges in progressing schiz-
ophrenia therapy. Front. Psychiatry 1:9. doi: 10.3389/
fpsyt.2010.00009
This article was submitted to Frontiers in Schizophrenia, a 
specialty of Frontiers in Psychiatry.
Copyright © 2010 Hajós. This is an open-access article sub-
ject to an exclusive license agreement between the authors 
and the Frontiers Research Foundation, which permits unre-
stricted use, distribution, and reproduction in any medium, 
provided the original authors and source are credited.
recognizing genetically based sub-types of 
the disease? While genetically-based per-
sonalized therapy is an attractive concept, 
still very little is happening in practice e.g. 
in schizophrenia, and most of the clinical 
trials fail in this ﬁ  eld. Are we after the right 
therapeutic targets? Do we undermine our 
efforts by not deﬁ  ning schizophrenia better, 
FIGURE 1 | Csontváry: The Solitary Cedar (Csontváry Museum, Pécs, Hungary).